NeoGenomics 将来の成長
Future 基準チェック /06
NeoGenomicsは、57.4%と8.5%でそれぞれ年率57.4%で利益と収益が成長すると予測される一方、EPSはgrowで56.6%年率。
主要情報
57.4%
収益成長率
56.64%
EPS成長率
| Healthcare 収益成長 | 18.3% |
| 収益成長率 | 8.5% |
| 将来の株主資本利益率 | n/a |
| アナリストカバレッジ | Good |
| 最終更新日 | 29 Apr 2026 |
今後の成長に関する最新情報
Recent updates
ナラティブの更新 • May 01
NEO: Expanded Test Access And Coverage Will Support Long Term Upside
Analysts have revised their fair value estimate for NeoGenomics from $17.00 to about $23.43. This change reflects updated assumptions for long term revenue growth, profit margins, and a higher future P/E multiple.
ナラティブの更新 • Apr 17
NEO: Medicare Test Coverage Will Support Bullish Repricing Through 2026 Guidance
Analysts have trimmed their price target on NeoGenomics from about $14.81 to roughly $14.19, citing updated assumptions for fair value, revenue growth, profit margin and future P/E that modestly reset expectations while keeping the broader thesis intact. What's in the News PanTracer LBx received coverage from the Centers for Medicare & Medicaid Services’ MolDX program under LCD L38043.
ナラティブの更新 • Apr 03
NEO: Expanded Genomic Test Coverage Will Support Stronger Outlook For 2026
Analysts have raised their price target on NeoGenomics from $12.00 to $13.00, citing updated assumptions for growth, profitability, discount rate, and a higher future P/E multiple. What's in the News PanTracer LBx liquid biopsy test received coverage from the Centers for Medicare & Medicaid Services’ MolDX program under LCD L38043, expanding access for Medicare patients to blood based comprehensive genomic profiling across more than 500 genes with a seven day turnaround (Key Developments).ナラティブの更新 • Mar 19
NEO: New Medicare Coverage Will Drive Bullish Repricing Through 2026 Guidance
Analysts have kept their $14.81 price target for NeoGenomics unchanged, citing stable modeled revenue growth, profit margins, and future P/E assumptions as the basis for maintaining their view. What's in the News Medicare, through the MolDX program, granted coverage for NeoGenomics' PanTracer LBx liquid biopsy test for plasma based genomic profiling in solid tumors, expanding access for Medicare patients to a blood based comprehensive genomic profiling assay that evaluates more than 500 genes with a seven day turnaround (Key Developments).ナラティブの更新 • Mar 05
NEO: Legal Victory And 2025–2026 Guidance Will Drive Bullish Repricing
Analysts have raised their price target on NeoGenomics from about $14.43 to roughly $14.81, citing updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News NeoGenomics launched RaDaR ST, a circulating tumor DNA assay for molecular residual disease that uses patient specific, tumor informed panels and whole exome sequencing to track up to 48 tumor variants with an LOD95 of 11 ppm.ナラティブの更新 • Feb 19
NEO: Liquid Biopsy Expansion And Legal Win Will Support Long Term Upside
Analysts have kept their $17.00 price target for NeoGenomics unchanged, reflecting only small model tweaks to the discount rate, revenue growth assumptions, profit margin expectations, and future P/E that do not materially alter their overall view of the stock. What's in the News Issued earnings guidance for 2026 with expected consolidated revenue of US$793 million to US$801 million and a projected net loss of US$63 million to US$50 million.ナラティブの更新 • Feb 05
NEO: Fair Outlook Balances Leadership Transition Patent Win And Clinical Data
Narrative Update on NeoGenomics Analysts have lifted their implied fair value estimate for NeoGenomics to US$12.00 per share, citing updated assumptions around revenue growth, discount rate, profit margin and future P/E as the key drivers behind the new price target framework. What’s in the News NeoGenomics announced a CFO succession plan, with Abhishek Jain joining as Executive Vice President on January 12, 2026 and scheduled to become CFO on March 2, 2026, as current CFO Jeff Sherman transitions toward retirement on April 14, 2026, after completing the fiscal 2025 reporting cycle.Seeking Alpha • Jan 25
NeoGenomics: Distribution Moat In Community Oncology
Summary NeoGenomics is transitioning from a commodity diagnostic provider to a comprehensive precision oncology platform, leveraging deep relationships with community oncologists. NEO’s clinical services revenue grew 18% YoY in Q3 2025, with high-value Next Generation Sequencing now nearly one-third of clinical revenue and outpacing market growth. The upcoming RaDaR ST launch in Q1 2026 positions NEO as a fast follower in the $20B MRD market, capitalizing on its established distribution and workflow integration. NEO trades at a significant discount to sector peers on EV/Sales and P/S, offering a margin of safety if execution on MRD and margin expansion materializes. Read the full article on Seeking Alphaナラティブの更新 • Jan 22
NEO: Legal Win And 2025 Guidance Will Drive Bullish Repricing
Analysts have raised their price target for NeoGenomics to about US$14.43 from roughly US$13.44, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that refine their view of the company’s long-term earnings power. What's in the News Issued preliminary unaudited guidance for the fourth quarter of 2025 with expected total revenue of about US$190 million and year over year growth of 11%, and full year 2025 revenue of about US$727 million with year over year growth of 10% (company guidance).ナラティブの更新 • Jan 08
NEO: Future Liquid Biopsy Data Pipeline Will Support Stronger Long Term Outlook
Analysts have lifted their fair value estimate for NeoGenomics from US$14.00 to US$17.00. They cite updated assumptions around revenue growth, profit margins and future P/E that they believe better reflect the company’s outlook.ナラティブの更新 • Dec 14
NEO: Upcoming Trial Readouts And Guidance Will Drive Bullish Repricing
Narrative Update on NeoGenomics Analysts have modestly raised their price target on NeoGenomics to approximately 13.44 dollars from about 13.17 dollars, citing slightly stronger long term revenue growth expectations and a marginally higher future earnings multiple, despite a nearly unchanged discount rate and profit margin outlook. What's in the News Upcoming SABCS 2025 presentations will showcase RaDaR 1.0 ctDNA data from the SURVIVE HERoes Phase III trial and CLEVER study in early breast cancer, supporting ctDNA guided surveillance and earlier intervention strategies (company announcement).ナラティブの更新 • Nov 29
NEO: Upcoming Research and Earnings Guidance Will Shape Market Expectations
Analysts have slightly raised their price target for NeoGenomics from $13.06 to $13.17 per share. This reflects updated assessments of future profitability and market growth potential.ナラティブの更新 • Nov 15
NEO: Upcoming Research Presentations Are Expected To Drive Solid Tumor Detection Momentum
Analysts have raised their fair value estimate for NeoGenomics from $11.72 to $13.06. This change is attributed to slightly improved revenue growth projections, as well as a modest increase in profit margins and future valuation multiples.ナラティブの更新 • Nov 01
NEO: Upcoming Research Presentations Will Accelerate Future Oncology Diagnostic Opportunities
Analysts have raised their price target for NeoGenomics from $10.44 to $11.72 per share. They cite marginal improvements in projected revenue growth and profit margin estimates.ナラティブの更新 • Oct 18
Advanced Oncology Diagnostics And NGS Capabilities Will Create Future Opportunities
Analysts have raised their price target for NeoGenomics from $9.78 to $10.44 per share, citing slightly improved revenue growth projections and a modestly higher future price-to-earnings multiple. What's in the News NeoGenomics announced the presentation of key MRD assay data, including results from interventional therapy trials, at the upcoming ESMO Congress 2025 in Berlin.ナラティブの更新 • Aug 30
Advanced Oncology Diagnostics And NGS Capabilities Will Create Future Opportunities
The higher analyst price target for NeoGenomics reflects an expansion in its future P/E multiple despite stable revenue growth forecasts, resulting in a revised fair value of $9.78. What's in the News U.S. District Court invalidated certain Natera patents asserted against NeoGenomics’ RaDaR v1.1 test, but the decision does not affect the '035 patent that previously led to a permanent injunction on RaDaR v1.0. NeoGenomics launched NEO PanTracer LBx, a blood-based comprehensive genomic profiling (CGP) test targeting the expanding liquid biopsy market and enhancing its pan-solid tumor CGP portfolio.分析記事 • Aug 27
Would NeoGenomics (NASDAQ:NEO) Be Better Off With Less Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Jul 30
Market Cool On NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues Pushing Shares 27% Lower
NeoGenomics, Inc. ( NASDAQ:NEO ) shareholders won't be pleased to see that the share price has had a very rough month...分析記事 • May 23
Take Care Before Jumping Onto NeoGenomics, Inc. (NASDAQ:NEO) Even Though It's 25% Cheaper
Unfortunately for some shareholders, the NeoGenomics, Inc. ( NASDAQ:NEO ) share price has dived 25% in the last thirty...
新しいナラティブ • Mar 23
PanTracer Launch And MRD Collaboration Will Strengthen Future Cancer Testing Leadership
NeoGenomics' strategic investments and collaborations are expected to enhance customer experiences, boost test volumes, and strengthen competitive positioning in MRD monitoring and Heme testing.分析記事 • Mar 08
NeoGenomics, Inc.'s (NASDAQ:NEO) Stock Retreats 28% But Revenues Haven't Escaped The Attention Of Investors
Unfortunately for some shareholders, the NeoGenomics, Inc. ( NASDAQ:NEO ) share price has dived 28% in the last thirty...Seeking Alpha • Feb 28
NeoGenomics: Decent Fundamentals, But Still Overvalued
Summary NeoGenomics is rated a Hold due to the intrinsic value being lower than the current price, and the company's negative net income and FCF. Despite revenue growth and increasing clinical volume, NeoGenomics missed revenue estimates, causing a 15.50% drop in the stock price. NeoGenomics shows promising long-term growth potential with rising cancer cases and improving ROIC, but negative profitability is a concern. Intrinsic value calculations using the Graham's Formula and DCF model suggest the stock may not yet be done falling. I am recommending caution. Read the full article on Seeking Alpha分析記事 • Feb 18
Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Jan 14
What You Can Learn From NeoGenomics, Inc.'s (NASDAQ:NEO) P/S After Its 29% Share Price Crash
NeoGenomics, Inc. ( NASDAQ:NEO ) shares have had a horrible month, losing 29% after a relatively good period...分析記事 • Nov 23
NeoGenomics, Inc. (NASDAQ:NEO) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable
NeoGenomics, Inc. ( NASDAQ:NEO ) shareholders are no doubt pleased to see that the share price has bounced 25% in the...分析記事 • Oct 16
Is NeoGenomics (NASDAQ:NEO) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Aug 01
Investors Appear Satisfied With NeoGenomics, Inc.'s (NASDAQ:NEO) Prospects As Shares Rocket 29%
NeoGenomics, Inc. ( NASDAQ:NEO ) shareholders would be excited to see that the share price has had a great month...分析記事 • Jul 15
Is NeoGenomics (NASDAQ:NEO) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2028 | 965 | -21 | N/A | N/A | 6 |
| 12/31/2027 | 881 | -37 | N/A | 74 | 12 |
| 12/31/2026 | 800 | -58 | N/A | 39 | 12 |
| 3/31/2026 | 746 | -99 | -5 | 22 | N/A |
| 12/31/2025 | 727 | -108 | -22 | 5 | N/A |
| 9/30/2025 | 709 | -113 | -17 | 14 | N/A |
| 6/30/2025 | 689 | -104 | -19 | 14 | N/A |
| 3/31/2025 | 672 | -78 | -32 | 8 | N/A |
| 12/31/2024 | 661 | -79 | -34 | 7 | N/A |
| 9/30/2024 | 644 | -78 | -22 | 15 | N/A |
| 6/30/2024 | 628 | -79 | -30 | 0 | N/A |
| 3/31/2024 | 611 | -84 | -40 | -15 | N/A |
| 12/31/2023 | 592 | -88 | -31 | -2 | N/A |
| 9/30/2023 | 575 | -96 | -50 | -23 | N/A |
| 6/30/2023 | 552 | -115 | -64 | -34 | N/A |
| 3/31/2023 | 530 | -126 | -82 | -50 | N/A |
| 12/31/2022 | 510 | -144 | -97 | -66 | N/A |
| 9/30/2022 | 497 | -163 | -120 | -82 | N/A |
| 6/30/2022 | 489 | -147 | -119 | -74 | N/A |
| 3/31/2022 | 486 | -36 | -115 | -58 | N/A |
| 12/31/2021 | 484 | -8 | -91 | -27 | N/A |
| 9/30/2021 | 485 | 49 | -65 | -1 | N/A |
| 6/30/2021 | 489 | 72 | -49 | 7 | N/A |
| 3/31/2021 | 454 | -11 | -30 | 11 | N/A |
| 12/31/2020 | 444 | 4 | -28 | 1 | N/A |
| 9/30/2020 | 425 | -5 | -25 | -1 | N/A |
| 6/30/2020 | 405 | -5 | -6 | 17 | N/A |
| 3/31/2020 | 419 | 3 | -11 | 10 | N/A |
| 12/31/2019 | 409 | 8 | N/A | 23 | N/A |
| 9/30/2019 | 378 | 2 | N/A | 35 | N/A |
| 6/30/2019 | 343 | 2 | N/A | 25 | N/A |
| 3/31/2019 | 309 | 6 | N/A | 37 | N/A |
| 12/31/2018 | 277 | 6 | N/A | 45 | N/A |
| 9/30/2018 | 262 | 8 | N/A | 35 | N/A |
| 6/30/2018 | 252 | -1 | N/A | 34 | N/A |
| 3/31/2018 | 246 | -9 | N/A | 34 | N/A |
| 12/31/2017 | 240 | -11 | N/A | 18 | N/A |
| 9/30/2017 | 239 | -27 | N/A | 12 | N/A |
| 6/30/2017 | 241 | -26 | N/A | 14 | N/A |
| 3/31/2017 | 242 | -29 | N/A | 13 | N/A |
| 12/31/2016 | 232 | -31 | N/A | 21 | N/A |
| 9/30/2016 | 211 | -18 | N/A | 24 | N/A |
| 6/30/2016 | 175 | -12 | N/A | 17 | N/A |
| 3/31/2016 | 136 | -7 | N/A | 14 | N/A |
| 12/31/2015 | 100 | -3 | N/A | 6 | N/A |
| 9/30/2015 | 98 | 0 | N/A | 5 | N/A |
| 6/30/2015 | 96 | 0 | N/A | 6 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: NEO今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: NEO今後 3 年間、利益が出ない状態が続くと予測されています。
高成長収益: NEO今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: NEOの収益 ( 8.5% ) US市場 ( 11.7% ) よりも低い成長が予測されています。
高い収益成長: NEOの収益 ( 8.5% ) 20%よりも低い成長が予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: NEOの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です
成長企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/22 00:11 |
| 終値 | 2026/05/22 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
NeoGenomics, Inc. 12 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。25
| アナリスト | 機関 |
|---|---|
| Bruce Jackson | Benchmark Company |
| Raymond Myers | Benchmark Company |
| Michael Ryskin | BofA Global Research |